Cell : The Lancet - Translational Medicine

Speaker

Andrew PHILLIPS, University College London, London, UK

Andrews PHILLIPS“The potency of current antiretroviral drug regimens is such that almost all people who are adherent to therapy maintain long-term viral suppression.  Given the low rate of viral load rebound and drug resistance, and the breadth of regimen options available, this is likely to be the case for the entire lifetimes of most people with HIV in well-resourced settings. What then are the residual excess disease risks among people with HIV who maintain viral suppression?"

Andrew Phillips is Professor of Epidemiology at UCL and has worked in the HIV field for the past 25 years, working on HIV observational cohorts (including the Royal Free Haemophilia Cohort, CASCADE, EuroSIDA, D:A:D, COHERE/PLATO), randomized trials (including INSIGHT SMART and START trials) and simulation modelling (HIV Synthesis model). Work on observational studies began with describing the link between time updated CD4 count and risk of AIDS and other aspects of HIV natural history, including effects of age and viral load. As effective therapy became available he moved on to examining effects of antiretroviral therapy in large clinical cohorts. Particular areas of interest have included virologic failure, drug resistance, adverse effects of ART, and the link between HIV and risk of non-AIDS diseases. He has latterly used individual-based simulation models of HIV transmission, progression and the effect of ART in an attempt to address public health questions not addressable in trials or analyses of observational studies, both in developed and developing country contexts. Much of his work involves close collaboration with Copenhagen HIV Programme (CHIP).

« Go Back

Organized by

Elsevier
Journal - The Lancet
Journal - Cell
Elsevier

Partners

Timothy Ray Brown
World AIDS Institute